ArticleACS macro letters2026
Reversible, Polymeric Complexation of Therapeutic Peptides Using Esterification.
Article in ACS macro letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Polyelectrolyte complexes permit the tunable, aqueous complexation of therapeutic peptides; however, their reliance on electrostatic and hydrophobic interactions limits complexation with weakly charged, hydrophilic peptides. While the peptide charge and hydrophobicity can be modified to encourage complexation, permanent modifications can hinder peptide activity and eventual release. Here, we show that esterifying the therapeutic peptide α-carboxyl terminus 11 (αCT11) reversibly increases its net charge and hydrophobicity, enabling complexation with anionic poly(methacrylic acid) and subsequent dissociation, as esters hydrolyze over 24 h. Prior to hydrolysis, hydrophobic aspartimide intermediates appear to promote aggregation, prolonging complexation. Further emphasizing the importance of hydrophobicity, replacing the aromatic polymer chain end with a less hydrophobic group abrogated complexation. Together, these studies showcase how esterification can be leveraged for reversible polymeric complexation of weakly charged, hydrophilic peptides and present exciting prospects for using polymer hydrophobicity to tune reversible complexation to meet patient and delivery method-specific needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.